# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jesse Owens (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML042-SYN-TD
- Date: 1979-09-30
- Fictional facility: St. Posthumous Health Center
- Fictional author: Clarence Whitfield-Arroyo, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Six weeks after left upper lobectomy: pathology and the plan from here. **S**

## History of present illness

Mr. Owens returns six weeks after his thoracoscopic left upper lobectomy. He went home on the third day, needed no opioid after discharge, and stopped acetaminophen two weeks ago. Pathology shows only 0.7 cm of residual cancer with 6 percent viable tumor, a major pathologic response, with clear margins and no cancer in any of 16 lymph nodes. Dr. Halvorsen-Pierce reviewed the options with him last week. He walks 2 km a day and starts the pulmonary rehabilitation program next week. He gets mildly short of breath on two flights of stairs. He has not smoked for four months. He has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Operation | Thoracoscopic left upper lobectomy with lymph node dissection; three days in hospital; no complications |
| Pathology | ypT1a N0 (0 of 16), R0, major pathologic response (6 percent viable tumor) |
| Tobacco | Abstinent four months on varenicline |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy returning; weight 74.6 kg; no fever |
| Respiratory | Positive | Mild breathlessness on two flights of stairs; no cough or sputum |
| Musculoskeletal | Positive | Mild aching at the port sites |
| Endocrine | Negative | No cold intolerance or constipation |
| Neurological | Negative | No numbness or tingling |
| Psychiatric | Negative | Relieved and hopeful; PHQ-2 0 |

6 systems reviewed. **S**

## Current medications

- Varenicline 1 mg oral tablet, one tablet by mouth twice daily after food, for 12 weeks and then a further 12 weeks to prevent relapse **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/76 mmHg; pulse 76 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 96% on room air; weight 74.6 kg; BMI 23.5 kg/m². All vital signs are synthetic.

Hemoglobin: 13.4 g/dL (low); White cell count: 7 10*3/uL; Absolute neutrophil count: 4.3 10*3/uL; Platelets: 246 10*3/uL; Creatinine: 1 mg/dL; eGFR (CKD-EPI 1974): 84 mL/min/1.73 m²; Glucose: 92 mg/dL; ALT: 24 U/L; AST: 22 U/L; Total bilirubin: 0.5 mg/dL; TSH: 4.6 mIU/L (high); Free T4: 1.1 ng/dL; PHQ-2: 0. All results are synthetic.

## Change since baseline

- Hemoglobin: 15.1 g/dL at baseline, 13.4 g/dL (low) at this visit **S**
- White cell count: 8.4 10*3/uL at baseline, 7 10*3/uL at this visit **S**
- Platelets: 262 10*3/uL at baseline, 246 10*3/uL at this visit **S**
- Creatinine: 1 mg/dL at baseline, 1 mg/dL at this visit **S**
- eGFR (CKD-EPI 1974): 84 mL/min/1.73 m² at baseline, 84 mL/min/1.73 m² at this visit **S**
- Glucose: 94 mg/dL at baseline, 92 mg/dL at this visit **S**
- ALT: 22 U/L at baseline, 24 U/L at this visit **S**
- AST: 21 U/L at baseline, 22 U/L at this visit **S**
- Total bilirubin: 0.6 mg/dL at baseline, 0.5 mg/dL at this visit **S**
- PHQ-2: 1 at baseline, 0 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 74.6 kg; blood pressure 122/76, pulse 76; oxygen saturation 96 percent |
| Respiratory | Breath sounds slightly reduced at the left apex; no crackles; port-site incisions healed |
| Cardiovascular | Regular rhythm; no edema |
| Lymph nodes | No supraclavicular nodes |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Left upper lobe adenocarcinoma after chemoimmunotherapy and lobectomy** (C34.12). Curative-intent treatment complete, with a major pathologic response and no residual nodal disease. More immunotherapy after surgery is an option used in other trials, but the regimen he received was designed to be given before surgery only, and the major response predicts a low risk of recurrence; after hearing the options from Dr. Halvorsen-Pierce, he chose surveillance. The KRAS G12C result stays on file in case of recurrence. **S**
   - Surveillance: history, examination and chest CT every six months for two to three years, then yearly low-dose CT.
   - No routine brain MRI, PET-CT or blood tumor markers for surveillance.
   - Pulmonary rehabilitation program from next week.
2. **After left upper lobectomy** (Z90.2). Recovering well; mild exertional breathlessness expected at six weeks. **S**
   - Pulmonary rehabilitation for 12 weeks.
3. **Nicotine dependence in early remission** (F17.211). Four months without a cigarette after 35 years; this is a major part of his cancer care. **S**
   - Continue varenicline to complete 24 weeks.
   - Relapse-prevention calls from the quitline.
4. **TSH on nivolumab**. TSH 4.6 with a normal free T4: settling after the grade 1 thyroiditis, no treatment needed. **S**
   - TSH and free T4 again in three months.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count with neutrophils and platelets | After treatment, as indicated | Completed today | Hemoglobin 13.4 (recovering), white cells 7.0, neutrophils 4.3, platelets 246 |
| Laboratory | Thyroid, liver, kidney and glucose tests after immunotherapy | After the last dose and for symptoms; thyroid every 6 to 12 weeks for a year after a rise | Completed today | TSH 4.6 (slightly high) with free T4 1.1; ALT 24, AST 22, bilirubin 0.5; creatinine 1.0, eGFR 84; glucose 92 |
| Imaging | Surveillance chest CT | Every six months for two to three years after curative treatment, then yearly low-dose CT | Due | First surveillance CT booked for six months after surgery |
| Imaging | Routine brain MRI, PET-CT and circulating tumor markers for surveillance | Not recommended in stage I to III | Not indicated | Not used without symptoms |
| Self-management | Pulmonary rehabilitation after lung resection | 6 to 12 week program after surgery | Referred | Starts next week |
| Self-management | Tobacco use and cessation treatment | Every visit | Completed today | Abstinent four months; varenicline to 24 weeks |
| Survey | Distress and depression screening | Every visit; PHQ-9 and GAD-7 at diagnosis and at treatment transitions | Completed today | PHQ-2 0 |
| Examination | Dyspnea and cough assessment | Every visit | Completed today | Mild breathlessness on two flights; no cough |
| Examination | Peripheral neuropathy after platinum | Every visit during and after platinum therapy | Completed today | None |
| Survey | Cancer-related fatigue | Every visit | Completed today | Mild, improving |
| Self-management | Immunizations after treatment | Per the adult schedule | Due | Influenza, COVID-19, RSV and zoster vaccines at the wellness visit in three weeks |

## Goal progress

- PET-CT, brain MRI, EBUS staging, tissue diagnosis, PD-L1 and comprehensive biomarker results and a tumor board plan within three weeks of the screening CT. Outcome by 1979-05-26: PET-CT in three days, brain MRI in four, EBUS in eight, tumor board in ten; PD-L1 and tissue sequencing back by the consultation, 15 days after the scan. **S**
- Stop smoking completely before treatment starts and stay stopped. Outcome by 1979-09-30: No cigarettes since day 1 of cycle 1, about four months; varenicline continued to complete 24 weeks. **S**
- Three cycles of chemoimmunotherapy before surgery without a delay of more than one week and without an immune-related adverse event of grade 2 or higher. Outcome by 1979-08-05: Three cycles on schedule; only a grade 1 rise in TSH, monitored without treatment. **S**
- Complete resection (R0) with systematic lymph node dissection within six weeks of the last cycle. Outcome by 1979-09-30: Thoracoscopic left upper lobectomy five weeks after cycle 3; R0; major pathologic response. **S**
- Back to walking 3 km most mornings by three months after surgery. Outcome by 1979-09-30: Walking 2 km a day six weeks after surgery and starting pulmonary rehabilitation. **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026), Aether Forge
- NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026), National Comprehensive Cancer Network
- Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021), American Society of Clinical Oncology
- Schneider BJ, et al. Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline Summary. JCO Oncol Pract 2020;16(2):83-86 (PMID 32045555) (2020), American Society of Clinical Oncology
- Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021), U.S. Preventive Services Task Force

## Follow-up

- Pulmonary rehabilitation from next week. Annual wellness visit in three weeks. Surveillance CT in about six months. Call for new cough, hemoptysis, bone pain, headache or weight loss. **S**
- Next scheduled visit 1979-10-21: subsequent annual wellness visit. **S**
